-
Tylenol maker Kenvue ousts CEO amid board's strategic review
-
RBC Capital's Ideas and Focus Picks Ahead of March Q Earnings
-
RBC trims Kenvue stock rating amid concerns over Skin Health & Beauty business
-
RBC Capital Downgrades Kenvue Inc (KVUE) to Sector Perform
-
Kenvue (KVUE) Prices 182.33M Share Secondary Offering at $20/sh
-
Kenvue Announces Pricing of Secondary Offering
-
Kenvue (KVUE) Announces Closing of IPO
-
Kenvue Announces Closing of Initial Public Offering
-
Kenvue (KVUE) Prices Upsized 172.18M Share IPO at $22/sh

